DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop (1) a reliable prognostic test to identify patients that are at risk for a poor outcome following standard therapy but who may benefit from a novel and personalised combinatorial therapy, and (2) a robust response test to predict the success of a novel combinatorial therapy as opposed to more aggressive solutions like a liver transplant.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847949. This website reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains.